Group 1 - The company Dong-E E-Jiao announced on January 5 that it has repurchased approximately 1.63 million shares, accounting for 0.25% of its total share capital, through a stock buyback program [1] - The highest transaction price for the repurchased shares was 49.24 yuan per share, while the lowest was 48.8 yuan per share [1] - The total amount spent on the share repurchase was approximately 79.99 million yuan [1] Group 2 - The news highlights the popularity of the iMoutai App, which quickly rose to the top of the Apple shopping chart, with 100,000 users placing orders for the product [1] - The limited availability of the product, priced at 1499 yuan, led to its rapid sell-out, indicating strong consumer demand [1] - Distributors are offering the same price as a promotional gesture, with 1000 boxes selling out quickly [1]

格隆汇1月5日丨东阿阿胶(000423.SZ)公布，截至2025年12月31日，公司通过股票回购专用证券账户， 以集中竞价交易方式累计回购股份数量为1,628,600股，约占公司总股本的0.25%，最高成交价为49.24 元/股，最低成交价为48.80元/股，成交总金额为79,992,687.96元人民币（不含交易费用）。本次回购符 合既定的回购股份方案以及相关法律法规的要求。 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-01 东阿阿胶股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 12 月 4 日召开第十 一届董事会第十五次会议，2025 年 12 月 22 日召开 2025 年第二次临时股东会， 审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使 用自有资金或自筹资金以集中竞价交易方式回购公司股份。 本次回购股份价格不超过人民币 72.08 元/股（含），按回购价格上限测算， 回购股份数量下限为 138.73 万股，上限为 277.47 万股，具体回购股份的价格和 数量，以回购期满时实际回购为准。本次回购股份实施期限自公司股东会审议通 过回购股份方案之日起不超过 12 个月，回购完成后的股份将全部注销并减少公 司注册资本。具体内容，详见公司在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于以集中竞价交易方式回购公司股份方案的公告》（公告编号： 20 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-02 东阿阿胶股份有限公司 关于参与设立华润医药产业投资基金二期进展 暨完成基金备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 为助力东阿阿胶股份有限公司（以下简称"公司"）发展战略落地，借助基 金管理人的专业及资源优势，围绕药品和健康消费品在内的滋补健康领域进行投 资布局、持续储备标的，公司于 2025 年 7 月 17 日召开第十一届董事会第十次会 议、第十一届监事会第九次会议，审议通过了《关于参与设立华润医药产业投资 基金二期暨关联交易的议案》。公司以自有资金认缴出资 6,000 万元人民币，参 与投资设立华润（成都）医药产业股权投资基金合伙企业（有限合伙），基金规 模为 10 亿元人民币。 基金名称：华润（成都）医药产业股权投资基金合伙企业（有限合伙） 管理人名称：深圳市华润资本股权投资有限公司 托管人名称：招商银行股份有限公司 备案日期：2025 年 12 月 30 日 公司将持续关注华润（成都）医药产业股权投资基金合伙企业（有限合伙） 的后续进展情况，并严 ...

Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

Core Insights - The collaboration between China Resources Vanguard and Dong'e Ejiao aims to provide high-quality health products to consumers focused on wellness and nutrition through the launch of the customized low-sugar Ejiao cake, "Peach Blossom Princess" [1][5] Group 1: Product Details - The "Peach Blossom Princess" product is made using traditional Ejiao production techniques, involving seven meticulous processes, resulting in a rich flavor [3] - The product features an optimized recipe that includes authentic Dong'e Ejiao combined with high-quality ingredients like walnut and black sesame, enhancing its nutritional value and taste [3] - The low-sugar Ejiao cake has reduced sugar content by approximately 80% compared to similar products and has received national low GI certification (GI value < 55), catering to health-conscious consumers [5] Group 2: Marketing and Sales Strategy - The product is exclusively available through China Resources Vanguard's online channels, with promotional activities running from December 15 to December 31, offering additional gifts and chances to win a special health journey [5] - The packaging design blends traditional aesthetics with modern style, featuring a light pink tone and convenient portable packaging for on-the-go consumption [5] - The partnership aims to leverage both companies' strengths in retail and health products to promote a new trend in health consumption, aligning with the ongoing "Healthy China" strategy and increasing consumer health awareness [6]

在新消费现代化浪潮中，东阿阿胶（000423.SH）正以科技创新为突破口，重塑阿胶产业的竞争力边 界。2025年，这家百年药企通过系统性强化研发体系，在理论创新、平台建设、机制改革等领域取得突 破性进展，不仅主导修订《中国药典》阿胶饮片标准，更在国际权威期刊发表道地阿胶补血活性肽等原 创成果，为产品升级与市场拓展注入强劲动能。 从气血理论的科学阐释到复方阿胶浆循证医学研究的国际认可，从双院士工作站的突破到15款健康消费 品的上市，东阿阿胶正以"科技+品牌"双轮驱动，推动传统滋补产业向智慧化、国际化迈进，为投资者 与行业呈现一份高质量发展的"东阿样本"。 东阿阿胶的这场战略变革始于三年多前，当时，公司积极响应"健康中国"战略，在华润集团"1246"模式 指引下，提出并落地"1238"战略，实施了一系列大刀阔斧的重塑革新，确定了药品与健康消费品"双轮 驱动"的业务增长模式。 在平台建设上，东阿阿胶以"一中心 三高地+N联合"模式打造产业创新引擎。该体系得到了进一步深 化："一中心"即国家胶类中药工程技术研究中心作为核心平台，年内取得多项标志性成果：率先发现道 地阿胶补血活性肽并建立专属检测方法，相关论文登上《Co ...

证券日报网讯 12月30日，东阿阿胶发布公告称，公司第十一届董事会第十六次会议审议通过《关于向 第一期限制性股票激励计划激励对象授予预留部分限制性股票的议案》《关于公司经营业绩合同的议 案》《关于确定2025年度审计费用的议案》等多项议案。 （编辑 丛可心） ...

格隆汇12月30日丨东阿阿胶(000423.SZ)公布，为深化企地交流，助力地方教育事业高质量发展，公司 拟向山东省教育基金会捐赠160万元（其中，现金150万元，实物折合10万元）。根据《深圳证券交易所 股票上市规则》及《公司章程》等相关规定，本议案无需提交股东会审议。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-84 东阿阿胶股份有限公司 关于向第一期限制性股票激励计划激励对象授予 预留部分限制性股票的公告 根据东阿阿胶股份有限公司（以下简称"公司"）2024 年年度股东大会的 授权，公司于 2025 年 12 月 30 日召开第十一届董事会第十六次会议，审议通过 了《关于向第一期限制性股票激励计划激励对象授予预留部分限制性股票的议 案》。现将有关事项公告如下： 一、已履行的相关审批程序和信息披露情况 1．2023 年 12 月 31 日，公司召开第十届董事会第二十二次会议和第十届监 事会第十三次会议，审议通过了《关于第一期限制性股票激励计划（草案）及其 摘要的议案》。 2．2025 年 1 月 10 日，公司召开第十一届董事会第五次会议和第十一届监 事会第五次会议，审议通过了《关于第一期限制性股票激励计划（草案修订稿） 及其摘要的议案》。 3．2025 年 4 月 24 日，公司披露了《关于限制性股票激励计划获得批复的 公告》。 4．202 ...